Navigation Links
2 beta blockers found to also protect heart tissue
Date:9/15/2008

DURHAM, N.C. A newly discovered chemical pathway that helps protect heart tissue can be stimulated by two of 20 common beta-blockers, drugs that are prescribed to millions of patients who have experienced heart failure.

Researchers from Duke University Medical Center tested 20 beta blockers and found that two of them -- alprenolol and carvedilol -- could stimulate a pathway recently found to protect heart tissue.

This finding could guide future drug development and in particular help heart failure patients, says Howard Rockman, M.D., senior author of the study and chief of the Duke Cardiology Division.

"To our surprise, we found that these two beta blockers can actually stimulate the beta receptor to activate a pathway in the cell that promotes cell survival. We have the first evidence that these two drugs have greater potential to repair the heart and to protect it, and possibly even to reverse some heart damage," Dr. Rockman said.

Until now, scientists believed that all beta-blockers worked by binding to and blocking the beta-adrenergic receptor, a molecule on the cell surface that responds to the hormone adrenalin. Blocking the receptor moderates increases in heart rate and heart function that could be damaging to patients whose hearts are already overstressed.

The two beta-blockers identified by the current study also serve to stimulate a different signaling beta-arrestin pathway. Beta arrestin is a protein known as an "off-switch" for beta-adrenergic receptors. These two drugs activated a beta-arrestin pathway that produces beneficial effects in the heart tissue.

"These two drugs were found to stimulate the pathway that produces certain proteins that are protective to the heart," Rockman said.

The new study, published online in Proceedings of the National Academy of Sciences, was funded by that National Institutes of Health.

"Based on these findings, we hope to design drugs that strongly bind in this way and activate this pathway," Rockman said. "We call these drugs biased-ligands or super receptor blockers, because they are designed to block the harmful actions of adrenalin at the beta receptor, but at a molecular level will activate other pathways that protect the cell." Rockman and colleagues discovered the heart-protection factors in a study published last year.

He noted that carvedilol (marketed for many years as Coreg and now as available in generic forms) is known as a very effective beta blocker, but alprenolol has not been fully developed as a beta blocker drug for heart failure patients. Beta blockers now are part of a standard of care for heart failure patients, who have weakened hearts and cannot tolerate much adrenalin, which is released all day long in people as they perform any exertion, even reading an exciting novel. Every year, 400,000 new cases of heart failure are diagnosed and the number is growing as the population ages.

"The next step is to test the drugs in animals to learn which might promote protection and which might cause more negative effects," Rockman said. "Cell studies can be tricky to replicate in organisms and we will have to see what happens, but these cellular results are very exciting and encouraging and could be a boon to heart failure patients."


'/>"/>

Contact: Mary Jane Gore
mary.gore@duke.edu
919-660-1309
Duke University Medical Center
Source:Eurekalert

Related biology news :

1. UT Knoxville wins 2 $3M National Science Foundation research and education grants
2. Substance found in fruits and vegetables reduces likelihood of the flu
3. New genes found for inflammatory bowel disease in children
4. New master switch found in the brain that regulates appetite and reproduction
5. The MDS Foundation supports the FDAs decision to expand vidaza label to include survival data
6. Genome of simplest animal reveals ancient lineage, confounding array of complex capabilities
7. Senescence in liver cells is found by CSHL scientists to help limit acute tissue damage
8. New York Stem Cell Foundation announces third annual Translational Stem Cell Research Conference
9. Toxoplasmosis found more severe in Brazil compared to Europe
10. Michael J. Fox Foundation PD Therapeutics Conference
11. Worlds smallest snake found in Barbados
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... Sweden , February 4, 2016 --> ... amounted to SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter ... profit amounted to SEK 517.6 M (loss: 30.0). Earnings per ... operating activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared ...
(Date:2/2/2016)... , Feb. 2, 2016 This BCC ... bioinformatic market by reviewing the recent advances in ... that drive the field forward. Includes forecast through ... Identify the challenges and opportunities that exist in ... software solution developers, as well as IT and ...
(Date:2/1/2016)... Canada , February 1, 2016 ... technological advancements to drive global touchfree intuitive gesture control ... --> Rising sales of consumer electronics coupled ... gesture control market size through ... consumer electronics coupled with new technological advancements to drive ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016  Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today provided ... Uniden in the Northern District of Texas ... forward.  Inter Partes Re-examination ("IPR") ... Patent Office.  The IPR was initiated on only certain ...
(Date:2/4/2016)... ... ... Many of the engineers at FireflySci, Inc. have been manufacturing quartz and ... cuvette manufacturers is their supercharged customer service and their extensive database of glass cuvette ... of inside information, they have recently revamped their manufacturing techniques to reduce lead times ...
(Date:2/3/2016)... Denmark , Feb. 3, 2016 Ascendis ... biotechnology company that applies its innovative TransCon technology to ... present at an upcoming investor conference.Event:2016 Leerink Partners Global ... NY Date:  , Wednesday, February 10, 2016 Time:  ... www.ascendispharma.com . --> An audio webcast ...
(Date:2/3/2016)... ON (PRWEB) , ... February 03, 2016 , ... ... and validating a series of potential targets (epitopes) specific to misfolded, propagating strains ... targets to create specific monoclonal antibody therapeutics for Alzheimer’s. , Following on from ...
Breaking Biology Technology: